These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 36650762)

  • 1. Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States.
    Safdar S; Ngonghala CN; Gumel AB
    Math Biosci Eng; 2023 Jan; 20(1):179-212. PubMed ID: 36650762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment.
    Ngonghala CN; Taboe HB; Safdar S; Gumel AB
    Appl Math Model; 2023 Feb; 114():447-465. PubMed ID: 36281307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical assessment of the impact of vaccine-type and immunity on the burden of COVID-19.
    Taboe HB; Asare-Baah M; Iboi EA; Ngonghala CN
    Math Biosci; 2023 Jun; 360():108981. PubMed ID: 36803672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical assessment of the roles of age heterogeneity and vaccination on the dynamics and control of SARS-CoV-2.
    Pant B; Gumel AB
    Infect Dis Model; 2024 Sep; 9(3):828-874. PubMed ID: 38725431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward Achieving a Vaccine-Derived Herd Immunity Threshold for COVID-19 in the U.S.
    Gumel AB; Iboi EA; Ngonghala CN; Ngwa GA
    Front Public Health; 2021; 9():709369. PubMed ID: 34368071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will vaccine-derived protective immunity curtail COVID-19 variants in the US?
    Mancuso M; Eikenberry SE; Gumel AB
    Infect Dis Model; 2021; 6():1110-1134. PubMed ID: 34518808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.
    Goh YS; Rouers A; Fong SW; Zhuo NZ; Hor PX; Loh CY; Huang Y; Neo VK; Kam IKJ; Wang B; Ngoh EZX; Salleh SNM; Lee RTC; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; ; ; Maurer-Stroh S; Wang CI; Leo YS; Ren EC; Lye DC; Young BE; Ng LFP; Renia L
    Front Immunol; 2022; 13():1031852. PubMed ID: 36451833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the SARS-CoV-2 Omicron variant dynamics in the United States with booster dose vaccination and waning immunity.
    León UA; Pérez AGC; Avila-Vales E
    Math Biosci Eng; 2023 Apr; 20(6):10909-10953. PubMed ID: 37322966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A log-odds system for waning and boosting of COVID-19 vaccine effectiveness.
    Szanyi J; Wilson T; Scott N; Blakely T
    Vaccine; 2022 Jun; 40(28):3821-3824. PubMed ID: 35643564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority.
    Fisman DN; Amoako A; Simmons A; Tuite AR
    PLoS One; 2024; 19(4):e0297093. PubMed ID: 38574059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses.
    Torresi J; Edeling MA; Nolan T; Godfrey DI
    Front Immunol; 2022; 13():914167. PubMed ID: 35911696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A generalized distributed delay model of COVID-19: An endemic model with immunity waning.
    Iyaniwura SA; Musa R; Kong JD
    Math Biosci Eng; 2023 Jan; 20(3):5379-5412. PubMed ID: 36896550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of age structure and vaccine prioritization on COVID-19 in West Africa.
    Taboe HB; Asare-Baah M; Yesmin A; Ngonghala CN
    Infect Dis Model; 2022 Dec; 7(4):709-727. PubMed ID: 36097593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
    Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand.
    Vattiatio G; Lustig A; Maclaren OJ; Plank MJ
    Epidemics; 2022 Dec; 41():100657. PubMed ID: 36427472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
    León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.